See more : AGL Energy Limited (AGL.AX) Income Statement Analysis – Financial Results
Complete financial analysis of BioVaxys Technology Corp. (BVAXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioVaxys Technology Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- MJardin Group, Inc. (MJARF) Income Statement Analysis – Financial Results
- Minera IRL Limited (MRLLF) Income Statement Analysis – Financial Results
- British & American Investment Trust PLC (BAF.L) Income Statement Analysis – Financial Results
- Kuala Lumpur Kepong Berhad (2445.KL) Income Statement Analysis – Financial Results
- JMC Projects (India) Limited (JMCPROJECT.NS) Income Statement Analysis – Financial Results
BioVaxys Technology Corp. (BVAXF)
About BioVaxys Technology Corp.
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 133.73K | 962.71K | 726.06K | 238.77K | 0.00 |
| General & Administrative | 2.11M | 2.94M | 4.00M | 775.10K | 229.91K |
| Selling & Marketing | 156.88K | 174.30K | 1.72M | 84.51K | 0.00 |
| SG&A | 2.27M | 3.12M | 5.72M | 859.61K | 229.91K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.40M | 4.08M | 6.44M | 1.10M | 229.91K |
| Cost & Expenses | 2.40M | 4.08M | 6.44M | 1.10M | 229.91K |
| Interest Income | 24.85K | 15.77K | 7.66K | 137.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.40M | 3.80M | 5.98M | 1.01M | 183.34K |
| EBITDA | 0.00 | 3.58M | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.40M | 3.58M | -6.42M | -1.09M | -229.70K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.28M | -7.92M | -478.68K | -93.55K | -33.54K |
| Income Before Tax | -7.69M | -11.73M | -6.46M | -1.10M | -230.12K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 7.64M | 9.93K | 71.69K | 29.66 |
| Net Income | -7.69M | -11.73M | -6.46M | -1.17M | -230.12K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.06 | -0.12 | -0.08 | -0.04 | -0.02 |
| EPS Diluted | -0.06 | -0.12 | -0.08 | -0.04 | -0.02 |
| Weighted Avg Shares Out | 134.15M | 98.18M | 82.93M | 30.05M | 11.02M |
| Weighted Avg Shares Out (Dil) | 134.14M | 98.18M | 82.93M | 28.21M | 10.39M |
BIOVAXYS ANNOUNCES COMPLETED DEBT SETTLEMENT
BioVaxys and Procare Health Agree to Termination of USA Distribution Agreement for Papilocare
BioVaxys enters non-binding discussions for major immunotherapeutics technology acquisition
BioVaxys in Non-Binding Discussions for Major Immunotherapeutics Technology Acquisition
BioVaxys Technology extends collaboration with Ohio State University as new Covid variant raises concerns
BioVaxys and The Ohio State University Extend Research Collaboration
BioVaxys Technology sells its medical software business, TAET Software
BioVaxys Technology acquires clinical study management company TAETSoftware; completes private placement
BioVaxys Technology finalizes US distribution deal with Procare Health Iberia for Papilocare Gel and Oral Immunocaps
BioVaxys Technology successfully tests production of ovarian cancer vaccine using a patient's ovarian tumor
Source: https://incomestatements.info
Category: Stock Reports